MHM Magazine

References:1. NasrallahHA,EarlyW,CutlerAJ, etal .The safetyand tolerabilityofcariprazine in long-term treatmentof schizophrenia:aposthocpooledanalysis. BMCPsychiatry 2017;17:305.DOI10.1186/s12888-017-1459-z. 2. ArsovaS,BarsovaGK.PatientswithSchizophrenia and Social Contacts. J Med Sci 2016;4(3):388-391. http://dx.doi.org/10.3889/oamjms.2016.084. 3. Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsych Dis Trea t 2020:16 519–534. http://doi.org/10.2147/NDT.S225643 4. National Institute of Mental Health. Schizophrenia [Brochure] [online] [cited 5 February 2023]; Available from: https://www.nimh.nih.gov/sites/default/files/documents/health/publications/schizophrenia/schizophrenia.pdf. 5. Stahl SM. Mechanismofactionofcariprazine. CNSSpectrums 2016;21:123–127.doi:10.1017/S1092852916000043. 6. BarabassyA,SzatmáriB,Laszlovszky I, etal .NegativeSymptomsofSchizophrenia:Constructs,Burden,andManagement. IntechOpen 2018,Chapter4:43-62.http://dx.doi. org/10.5772/intechopen.73300. 7. Németh G, Laszlovszky I, Czobor P, et al . Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 2017;389:1103-1113. DOI: http://dx.doi.org/10.1016/S0140-6736(17)30060-0. 8. Durgam S, Starace A, Li D, et al . An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophr Res 2014;152:450-457. http:// dx.doi.org/10.1016/j.schres.2013.11.041. 9. DurgamS,CutlerAJ,LuK, etal .Cariprazine inAcuteExacerbationofSchizophrenia:AFixed-Dose,Phase3,Randomized,Double-Blind,Placebo-andActive-ControlledTrial. JClinPsychiatry 2015;76(12):e1574-e1582.Dx.doi.org/10.4088/ JCP.15m09997. 10. Kane JM, Zukin S, Wang Y, et al . Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia. Results From an International, Phase III Clinical Trial. J Clin Psychopharmacol 2015;35: 367–373. DOI: 10.1097/JCP.0000000000000346. 11. Marder S, FleischhackerWW, EarleyW, et al . Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol 2019;29:127-136. 12. Correll CU, Potkin SG, ZhongY, et al . Long-Term RemissionwithCariprazineTreatment inPatientswithSchizophrenia:APostHocAnalysisofaRandomized,Double-Blind,Placebo-Controlled,RelapsePreventionTrial. JClinPsychiatry 2019;80(2):18m12495.https://www.doi.org/10.4088/JCP.18m12495. 13. DurgamS,EarleyW, LiR, etal .Long-term cariprazine treatment for thepreventionof relapse inpatientswith schizophrenia:A randomized,double-blind,placebo-controlled trial. SchizophrRes 2016;176:264-271.http://dx.doi.org/10.1016/j.schres.2016.06.030. 14. BarabássyA,SebeB,AcsaiK, etal . SafetyandTolerabilityofCariprazine inPatientswithSchizophrenia:APooledAnalysisofEightPhase II/IIIStudies. NeuropsychDisTreat 2021:17957–970.http://doi.org/10.2147/NDT.S301225. COMING SOON! CARIPRAZINE: Adcock IngramLimitedCo.Reg.No.1949/034385/06,PrivateBagX69,Bryanston,2021,SouthAfrica.CustomerCare:0860ADCOCK /232625.www.adcock.com.www.adcock.com.2023051810280645May2023. Unique pharmacological profile 5 The only antipsychotic with proven superiority to other second-generation antipsychotics in the treatment of predominantly negative symptoms of schizophrenia 6,7 Proven efficacy in the management of positive and cognitive symptoms 8-11 Sustained long-term remission and improvement of functionality 12,13 Generally well tolerated 13,14